Aug. 15 at 6:01 PM
$APRE AstraZeneca's setbacks with first-generation DNA damage response (DDR) inhibitors—such as class-limiting toxicities and narrow therapeutic windows—pave a clear path for Aprea Therapeutics Wee1 and ATR inhibitors.
AstraZeneca's early candidate adavosertib suffered from severe cumulative bone marrow and gastrointestinal toxicities because they hit unintended kinases.
Earlier trials proved that targeting the WEE1 and ATR axes is biologically effective, but the old molecules could not be safely dosed high enough or long enough.
Aprea’s lead oral WEE1 inhibitor, APR-1051, specifically avoids the off-target PLK liabilities of older generations, translating to lower observed side effects. Aprea uses a sharp genomic selection strategy to ensure high efficacy where the vulnerability is densest.
Early Phase 1 readouts (such as updates from the Aprea 1051 trial show encouraging tumor shrinkage and partial responses without hitting the severe myelosuppression walls that stalled legacy drugs
